LYCA insider filings
Lycia Therapeutics, Inc. — 20 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-26. Screen LYCA transaction legs live →
Insider transaction summary — last 90 days
2026-07-29 to 2026-10-27, from the filings listed below: 20 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
+2 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Lycia Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Fischer Laurent — Director | Grant/award (A): 13,307 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Henderson Jane — Director | Grant/award (A): 57,666 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | RIEFLIN WILLIAM JL — Director | Grant/award (A): 24,840 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Touami Sofia — Chief Business Officer | Grant/award (A): 68,755 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Lee Chin Hyok — Chief Medical Officer, 10% owner | Grant/award (A): 73,191 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Staben Steven — Chief Scientific Officer, 10% owner | Grant/award (A): 110,896 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Bachrodt Amy — Chief Financial Officer, 10% owner | Grant/award (A): 399,746 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Trombley Aetna Wun — President and CEO, Director, 10% owner | Grant/award (A): 443,586 (derivative) @ $0 | EDGAR |
| 2026-10-22 | 3 | ELI LILLY & Co — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management III, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners XP, L.P. — 10% owner VHCP Management XP, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Bertozzi Carolyn R — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Versant Ventures VII GP, L.P. — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Henderson Jane — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Fischer Laurent — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Touami Sofia — Chief Business Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | RIEFLIN WILLIAM JL — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Staben Steven — Chief Scientific Officer, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Lee Chin Hyok — Chief Medical Officer, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Bachrodt Amy — Chief Financial Officer, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Trombley Aetna Wun — President and CEO, Director, 10% owner | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — Lycia Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-26 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Lycia Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299300 (S-1) — latest: Final prospectus (424B4), filed 2026-10-23
GET https://api.filingpulse.io/v1/insider-trades?ticker=LYCA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs